AHA, others urge DEA to increase annual caps for controlled substances
The AHA, American Medical Association, American Society of Anesthesiologists, American Society of Health-System Pharmacists, and Association for Clinical Oncology are urging the Drug Enforcement Agency to allow drug manufacturers and 503B outsourcing facilities to receive increased annual production quota controlled-substance allocations during the COVID-19 crisis.
Doing so, the organizations say in a letter to the DEA, will allow them to meet “legitimate, and absolutely critical, patient care needs” caused by huge spikes in demand for morphine, hydromorphone, fentanyl and other opioids because of the number of patients requiring ventilation
Related News Articles
Headline
The AHA June 7 submitted comments on a discussion draft of the Drug Shortage Prevention and Mitigation Act, bipartisan legislation proposing to provide…
Blog
The inability of many patients to obtain needed drug therapies due to either high prices or shortages has negatively affected patient outcomes.1 Nearly 30% of…
Headline
ASHP tracked a record 323 active drug shortages during the first quarter of 2024, surpassing the previous record of 320 shortages in 2014.“Some of the most…
Headline
The Department of Health and Human Services April 2 released a white paper proposing policy solutions for Congress and others to prevent drug shortages and…
Headline
In a statement submitted to the House Ways and Means Committee for a hearing Feb. 6 on chronic drug shortages, AHA recommended Congress enact legislation to…
Headline
Reps. Doris Matsui, D-Calif., and Larry Bucshon, R-Ind., Jan. 12 introduced a House version of the Mapping America’s Pharmaceutical Supply Act, legislation…